MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Abeona Therapeutics DSO Ratio 2011-2026 | ABEO
Annual DSO Ratio Abeona Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 387 | 182 | - | - | 9.86 | 46.7 | 50.9 | 40.4 | 13.8 | 13.2 | 69.6 | 65.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 387 | 9.86 | 88 |
Quarterly DSO Ratio Abeona Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 69.4 | 45.6 | 396 | - | - | - | - | - | 45.6 | - | - | - | - | - | - | - | 4.32 | 26.8 | 3.3 | - | 44.6 | 45 | 56.7 | - | 61.5 | 52.9 | 46.4 | - | 36.8 | 37.2 | 26.5 | - | 13.5 | 12.9 | 23.9 | - | 35.7 | 14.5 | 34.1 | - | 88 | 111 | 29.1 | - | 29.2 | 203 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 396 | 3.3 | 59 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
173 | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
22.1 | $ 3.24 | 3.35 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.82 | 4.22 % | $ 4.47 M | China |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 231.26 | 0.1 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
BioCardia
BCDA
|
101 | $ 1.37 | 7.87 % | $ 29 M | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 11.29 | -2.5 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 14.61 | 1.71 % | $ 214 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
47.5 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.64 | - | $ 16.6 M | USA |
 |
CorMedix
CRMD
|
130 | $ 6.57 | 0.46 % | $ 473 K | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |